{
  "disease": "Rhabdomyosarcoma (RMS)",
  "mcqs": [
    {
      "question": "From which cells does Rhabdomyosarcoma arise?",
      "options": {
        "A": "Epithelial cells",
        "B": "Primitive mesenchymal cells with skeletal muscle differentiation",
        "C": "Neural cells",
        "D": "Cartilage cells"
      },
      "correct_answer": "B",
      "explanation": "Rhabdomyosarcoma arises from primitive mesenchymal cells with skeletal muscle differentiation."
    },
    {
      "question": "Which of the following is a non-modifiable risk factor for Rhabdomyosarcoma?",
      "options": {
        "A": "Smoking",
        "B": "Genetic syndromes such as Li-Fraumeni syndrome",
        "C": "Alcohol consumption",
        "D": "Physical inactivity"
      },
      "correct_answer": "B",
      "explanation": "Non-modifiable risk factors include genetic syndromes such as Li-Fraumeni syndrome."
    },
    {
      "question": "At what ages do the peaks of Rhabdomyosarcoma incidence occur?",
      "options": {
        "A": "0-1 years and 5-10 years",
        "B": "2-6 years and 10-18 years",
        "C": "1-3 years and 8-12 years",
        "D": "5-10 years and 15-20 years"
      },
      "correct_answer": "B",
      "explanation": "Rhabdomyosarcoma has a bimodal distribution with peaks at 2–6 years and 10–18 years."
    },
    {
      "question": "Which immunohistochemical marker is positive in Rhabdomyosarcoma?",
      "options": {
        "A": "CD20",
        "B": "Desmin",
        "C": "S100",
        "D": "CK7"
      },
      "correct_answer": "B",
      "explanation": "Immunohistochemistry for Rhabdomyosarcoma is positive for desmin, myogenin, and MyoD1."
    },
    {
      "question": "Which of the following defines the high-risk group for Rhabdomyosarcoma according to COG stratification?",
      "options": {
        "A": "Embryonal RMS with localized disease",
        "B": "Alveolar RMS with localized disease",
        "C": "Metastatic disease or FOXO1-fusion positive alveolar RMS",
        "D": "Unresectable embryonal RMS"
      },
      "correct_answer": "C",
      "explanation": "The high-risk group includes metastatic disease or FOXO1-fusion positive alveolar RMS."
    },
    {
      "question": "Which syndrome is associated with germline TP53 mutations and increased risk of Rhabdomyosarcoma?",
      "options": {
        "A": "Neurofibromatosis type 1",
        "B": "Li-Fraumeni syndrome",
        "C": "Beckwith-Wiedemann syndrome",
        "D": "Costello syndrome"
      },
      "correct_answer": "B",
      "explanation": "Li-Fraumeni syndrome, characterized by germline TP53 mutations, is associated with Rhabdomyosarcoma."
    },
    {
      "question": "A 10-year-old with metastatic rhabdomyosarcoma is most likely to have involvement of which site?",
      "options": {
        "A": "Liver",
        "B": "Lungs",
        "C": "Bone marrow",
        "D": "Brain"
      },
      "correct_answer": "B",
      "explanation": "The lungs are the most common site of metastasis in rhabdomyosarcoma, followed by bone marrow and bones, which guides staging evaluations."
    },
    {
      "question": "Which imaging modality is preferred for local staging of Rhabdomyosarcoma?",
      "options": {
        "A": "CT scan",
        "B": "MRI",
        "C": "PET-CT",
        "D": "Ultrasound"
      },
      "correct_answer": "B",
      "explanation": "MRI is preferred for local staging of Rhabdomyosarcoma."
    },
    {
      "question": "What is the backbone chemotherapy regimen for Rhabdomyosarcoma?",
      "options": {
        "A": "VAC (Vincristine, Actinomycin-D, Cyclophosphamide)",
        "B": "ABVD (Doxorubicin, Bleomycin, Vinblastine, Dacarbazine)",
        "C": "CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone)",
        "D": "ICE (Ifosfamide, Carboplatin, Etoposide)"
      },
      "correct_answer": "A",
      "explanation": "The VAC regimen (Vincristine, Actinomycin-D, Cyclophosphamide) is the backbone chemotherapy for Rhabdomyosarcoma."
    },
    {
      "question": "How often should follow-up occur for the first 2 years after treatment for Rhabdomyosarcoma?",
      "options": {
        "A": "Monthly",
        "B": "Every 3-4 months",
        "C": "Every 6 months",
        "D": "Annually"
      },
      "correct_answer": "B",
      "explanation": "Follow-up should occur every 3–4 months for the first 2 years."
    }
  ]
}